Several promising HDACis, including abexinostat (PCI-24781), panobinostat (LBH589), and vorinostat (suberoylanilide hydroxamic acid [SAHA]), are available for the treatment of ER+ breast cancer. The gene discussed is ESR1; the disease is breast cancer.